Can DNA glitches predict prostate cancer treatment success?
NCT ID NCT04489719
First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times
Summary
This study looks at men with advanced prostate cancer that has spread to the bones. Researchers want to see if certain DNA repair problems in the cancer cells make the drug radium-223 work better or worse. The goal is to help doctors choose the best treatment for each patient in the future. About 48 men will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bozeman Health Deaconess Hospital
ACTIVE_NOT_RECRUITINGBozeman, Montana, 59715, United States
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
-
Johns Hopkins University
RECRUITINGBaltimore, Maryland, 21287, United States
-
University of Wisconsin-Madison
RECRUITINGMadison, Wisconsin, 53705, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a three-drug cocktail outsmart resistant prostate cancer?
- Precision radiation may tame rising PSA after prostate surgery
- Real-Time nerve monitoring during spine surgery could predict bladder and bowel function
- Blood test could tell doctors when to stop prostate cancer treatment early
- Could a stronger first dose of targeted radiation beat back advanced prostate cancer?